Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00721357 · ClinicalTrials.gov registry record

Skeletal Muscle Properties and the Metabolic Cost of Walking Post-stroke

A clinical trial, sponsored by VA Office of Research and Development.

Completed
Registry status
30
Enrollment target

NCT00721357: Completed study, sponsored by VA Office of Research and Development.

NCT00721357 is a clinical trial that has completed, run by VA Office of Research and Development. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00721357 has completed, sponsored by VA Office of Research and Development.

COMPLETED
Registry status
30 participants
Enrollment target

Study Summary

Of the \~700,000 persons who suffer a stroke each year, only 50% recover the ability to perform unlimited community walking. One mechanism contributing to locomotor dysfunction post-stroke is an increased metabolic cost of walking relative to neurologically healthy individuals 2-4. This increased cost likely limits the amount of walking performed, which further reduces functional capacity, thus contributing to long-term spiral of disability and decreased quality of life in these persons. In addition to increased metabolic cost, increased estimates of mechanical work are also characteristic of hemiparetic walking 2,29. Interestingly, although estimates of mechanical work reflect work done by locomotor muscles, little is known about the impact that peripheral muscle properties have on estimates of mechanical work. Furthermore, questions concerning how these properties relate to the increased metabolic cost of walking remain unanswered. The short-term objective and purpose of the proposed research is to determine the extent to which peripheral muscle characteristics, as well as estimates of muscle mechanical energy expenditure (MMEE), relate to the metabolic cost of walking post-stroke.

Primary Outcome

Amount of oxygen consumed during walking at self-selected speed normalized to speed

Interventions

  • BEHAVIORAL Treadmill walking
  • OTHER Magnetic resonance spectroscopy

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2008-08
Est. Completion 2013-09
VA Office of Research and Development

1,668 total trials

What the finished NCT00721357 record still lists

NCT00721357 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.

The record links to 0 conditions, and to 2 interventions - of which Treadmill walking is the first listed.

NCT00721357 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00721357 about?

NCT00721357 is a clinical study titled "Skeletal Muscle Properties and the Metabolic Cost of Walking Post-stroke". Of the \~700,000 persons who suffer a stroke each year, only 50% recover the ability to perform unlimited community walking. One mechanism contributing to locomotor dysfunction post-stroke is an increased metabolic cost of walking relative to neurologically healthy individuals 2-4. This increased co...

What is the current status of trial NCT00721357?

This trial is currently completed. The enrollment target is 30 participants. The study started on 2008-08. Estimated completion is 2013-09.

What interventions are being tested in trial NCT00721357?

The interventions under investigation include: Treadmill walking (BEHAVIORAL), Magnetic resonance spectroscopy (OTHER).

Who is sponsoring clinical trial NCT00721357?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00721357, the US trial registry maintained by the National Library of Medicine. NCT00721357 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.